SELECT COUNTRY

VIEW ALL

AFRICA

AMERICAS

ASIA

EUROPE

OCEANIA

ALGERIA ANGOLA ARGENTINA AUSTRALIA AZERBAIJAN BAHREIN BELGIUM BENIN BOLIVIA BOTSWANA BRAZIL BRUNEI BURKINA FASO CAMEROON CANADA CENTRAL AFRICAN REPUBLIC CHAD CHILE CHINA COLOMBIA COTE D’IVOIRE CZECH REPUBLIC DOMINICAN REPUBLIC DRC ECUADOR EGYPT ETHIOPIA FINLAND FRANCE GABON GHANA GREENLAND GUINEA HUNGARY ICELAND INDIA INDONESIA IRAN IRAQ ITALY KAZAKHSTAN KENYA KUWAIT LESOTHO LIBERIA MADAGASCAR MALAWI MALAYSIA MALI MAURITANIE MEXICO MONGOLIA MOROCCO MOZAMBIQUE NAMIBIA NETHERLANDS NICARAGUA NIGER NIGERIA NORWAY PANAMA PAPUA NEW GUINEA PERU PHILIPPINES POLAND QATAR REPUBLIC OF CONGO RUSSIA RWANDA SENEGAL SINGAPORE SLOVENIA SOMALI SOUTH AFRICA SOUTH KOREA SPAIN SWEDEN TAIWAN TANZANIA THAILAND TOGO TRINDAD & TOBAGO TURKEY TURKMENISTAN UAE UGANDA UKRAINE UNITED KINGDOM UNITED STATES VENEZUELA VIETNAM ZAMBIA ZIMBABWE

UNITED STATES: LATEST INTERVIEWS MORE INTERVIEWS

Tom Sellig

CEO, ADARE PHARMA SOLUTIONS

"Our reputation is based on how we deploy technologies to solve complex formulation challenges."

United States

Pharma & Life Sciences

Mark Jara

PRINCIPAL AND MANAGING DIRECTOR, RXS

"Tele-health tactics gained momentum and our clients made their pivot, like other industries, to fully remote operations. RxS, with our technology-forward approach, was prepared for the shift."

United States

Pharma & Life Sciences

Candice Long

PRESIDENT – US INFECTIOUS DISEASES & VACCINES, JANSSEN PHARM...

"In vaccines, we are progressing late-stage programs of break-through vaccines against diseases where vaccines are not currently available, such as RSV and multidrug resistant bacterial infections, including ExPEC and Staphylococcus aureus."

United States

Pharma & Life Sciences

Joe Panetta

PRESIDENT & CEO, BIOCOM CALIFORNIA

"We experienced explosive growth across the state and consequently adopted a new name: Biocom California."

United States

Pharma & Life Sciences

UNITED STATES: LATEST ARTICLES

United States

Pharma & Life Sciences

Funding Environment: Life Sciences Enter the Mainstream

April 20, 2021

The past 12 months been transformative for the life science industry in USA, and GBR explores how the funding environment has evolved to provide the influx of capital to sustain its innovations.